The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law A Note on Peptides by Shantanu Out of Singapore FDA Moves to Reevaluate Several Peptides American Med Spa Association BPC 157 What Athletes Need to Know About Legality, Safety and Efficacy Training & Conditioning of the Federal Food, Drug, and Cosmetic Act (FDCA).*